Assembly Biosciences (ASMB) Long-Term Investments (2015 - 2022)
Assembly Biosciences (ASMB) posted quarterly Long-Term Investments of $11.7 million for Q4 2022, down 58.02% year-over-year from $28.0 million in Q4 2021, and down 1.38% quarter-over-quarter from $11.9 million in Q2 2022.
Assembly Biosciences (ASMB) Long-Term Investments (2015 - 2022) Analysis & Trends
Assembly Biosciences' Long-Term Investments history runs 6 years deep, the most recent figure standing at $11.7 million for Q4 2022.
- In Q4 2022, Long-Term Investments fell 58.02% year-over-year to $11.7 million; the TTM figure through Dec 2022 stood at $11.7 million (down 58.02% YoY), while the FY2022 annual figure was $11.7 million, down 58.02% from the prior year.
- Long-Term Investments for Q4 2022 stood at $11.7 million, down from $11.9 million in the prior quarter.
- The five-year high for Long-Term Investments was $28.0 million in Q4 2021, with the low at $2.2 million in Q2 2018.
- The 3-year median for Long-Term Investments is $11.8 million (2022), against an average of $14.4 million.
- The sharpest annual moves came in 2018 and 2022: Long-Term Investments declined 26.75% in 2018, then tumbled 58.02% in 2022.
- Assembly Biosciences' Long-Term Investments stood at $2.2 million in 2018, then jumped by 1169.09% to $28.0 million in 2021, then sank by 58.02% to $11.7 million in 2022.
- Business Quant data shows ASMB's Long-Term Investments at $11.7 million in Q4 2022, $11.9 million in Q2 2022, and $23.5 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 11.74 Mn |
| Jun 30, 2022 | 11.91 Mn |
| Mar 31, 2022 | 23.46 Mn |
| Dec 31, 2021 | 27.97 Mn |
| Sep 30, 2021 | 9.18 Mn |
| Jun 30, 2018 | 2.20 Mn |
| Dec 31, 2017 | 3.35 Mn |
| Sep 30, 2017 | 1.00 Mn |
| Jun 30, 2017 | 3.01 Mn |
| Dec 31, 2016 | 2.44 Mn |
| Sep 30, 2016 | 7.90 Mn |
| Jun 30, 2016 | 11.17 Mn |
| Mar 31, 2016 | 23.39 Mn |
| Dec 31, 2015 | 23.39 Mn |
| Sep 30, 2015 | 31.19 Mn |
| Jun 30, 2015 | 31.44 Mn |